Tscan Therapeutics Total Liabilities

Tscan Therapeutics (TCRX) currently reports a total liabilities of $110M as of March 2026. That compares with $120M in the prior-year period — down 14.2% year over year. Use the charts on this page to explore Tscan Therapeutics's total liabilities history and peer comparisons.

Tscan Therapeutics's total liabilities decreased from $120M to $110M — a 14.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tscan Therapeutics reported $110M in total liabilities as of March 2026. That compares with $120M in the prior-year period — down 14.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.

Tscan Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRX with unrelated industries.